

B<sup>2</sup> therapeutically effective amount of pGLU-GLU-PRO-NH<sub>2</sub> as an active ingredient under time and conditions to treat said Glu induced neurotoxicity.

---

B<sup>3</sup> 10. (Twice Amended) A method of reducing Glu induced neurotoxicity in brain, spinal cord and/or retina comprising administering to a patient a composition comprising a therapeutically effective amount of (a) pGLU-GLU-PRO-NH<sub>2</sub> and (b) N-tert-Butyl- $\alpha$ -(2-sulfophenyl) nitron or a free radical scavenging nitron that enhances the effects of pGLU-GLU-PRO-NH<sub>2</sub> under time and conditions to treat said Glu induced neurotoxicity.

---

B<sup>4</sup> 13. (Amended) A method of preventing Glu induced neurotoxicity in brain, spinal cord and/or retina comprising administering to a patient a composition comprising a therapeutically effective amount of pGLU-GLU-PRO-NH<sub>2</sub> as an active ingredient under time and conditions to treat said Glu induced neurotoxicity.

---

Please add the following claims:

---

14. (New) The composition of claim 1, wherein said neuroprotective amount is about 0.5 to 10 mg per kilogram of body weight per dose.

B<sup>5</sup> 15. (New) The composition of claim 1, wherein said pharmaceutically acceptable carrier is one or more ingredients selected from the group consisting of: starch, sugar, flavoring agents, preservatives, water, organic co-solvents, flavor emulsions, oils and elixirs.

16. (New) The composition of claim 1, wherein said pharmaceutically acceptable carrier affords prolonged action or sustained release.

---